These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26807730)

  • 1. Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice.
    Korsten H; Ziel-van der Made AC; van Weerden WM; van der Kwast T; Trapman J; Van Duijn PW
    PLoS One; 2016; 11(1):e0147500. PubMed ID: 26807730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
    Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
    Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model.
    Korsten H; Ziel-van der Made A; Ma X; van der Kwast T; Trapman J
    PLoS One; 2009 May; 4(5):e5662. PubMed ID: 19461893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    van Duijn PW; Marques RB; Ziel-van der Made ACJ; van Zoggel HJAA; Aghai A; Berrevoets C; Debets R; Jenster G; Trapman J; van Weerden WM
    Prostate; 2018 Sep; 78(13):1013-1023. PubMed ID: 30133757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice.
    Takahara K; Ibuki N; Ghaffari M; Tearle H; Ong CJ; Azuma H; Gleave ME; Pollak M; Cox ME
    Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):239-47. PubMed ID: 23689346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium.
    Sutherland BW; Knoblaugh SE; Kaplan-Lefko PJ; Wang F; Holzenberger M; Greenberg NM
    Cancer Res; 2008 May; 68(9):3495-504. PubMed ID: 18451178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.
    Ratnacaram CK; Teletin M; Jiang M; Meng X; Chambon P; Metzger D
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2521-6. PubMed ID: 18268330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
    Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
    PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
    Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KLF5 inhibits angiogenesis in PTEN-deficient prostate cancer by attenuating AKT activation and subsequent HIF1α accumulation.
    Ci X; Xing C; Zhang B; Zhang Z; Ni JJ; Zhou W; Dong JT
    Mol Cancer; 2015 Apr; 14():91. PubMed ID: 25896712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
    Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
    Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
    Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
    Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma.
    Koksal IT; Dirice E; Yasar D; Sanlioglu AD; Ciftcioglu A; Gulkesen KH; Ozes NO; Baykara M; Luleci G; Sanlioglu S
    Urol Oncol; 2004; 22(4):307-12. PubMed ID: 15283888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microautoradiographic quantitation of vascular endothelial growth factor mRNA levels in human prostate specimens containing normal and neoplastic epithelium.
    Woessner RD; Wright PS; Loudy DE; Wallace CD; Montgomery LR; Nestok BR
    Exp Mol Pathol; 1998; 65(1):37-52. PubMed ID: 9613925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.
    Nickerson T; Miyake H; Gleave ME; Pollak M
    Cancer Res; 1999 Jul; 59(14):3392-5. PubMed ID: 10416600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
    De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
    Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.
    Allott EH; Masko EM; Freedland AR; Macias E; Pelton K; Solomon KR; Mostaghel EA; Thomas GV; Pizzo SV; Freeman MR; Freedland SJ
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):196-203. PubMed ID: 29795142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer progression, metastasis, and gene expression in transgenic mice.
    Perez-Stable C; Altman NH; Mehta PP; Deftos LJ; Roos BA
    Cancer Res; 1997 Mar; 57(5):900-6. PubMed ID: 9041192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
    Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
    J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.